Premium
Biologics in the treatment of hidradenitis suppurativa: etanercept (preliminary report on clinical trial) and infliximab (case study)
Author(s) -
Adams David Richard
Publication year - 2006
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/j.0906-6705.2006.0436n.x
Subject(s) - etanercept , medicine , hidradenitis suppurativa , infliximab , placebo , adverse effect , ulcerative colitis , dermatology , clinical trial , drug , surgery , tumor necrosis factor alpha , pharmacology , pathology , alternative medicine , disease
A teenager with significant hidradenitis suppurativa (HS) and ulcerative colitis was treated with infliximab infusion. The response was rapid and dramatic. This response led us to develop and gain approval for a 20 patient, 6‐month investigator‐initiated study using another anti‐tumor necrosis alpha agent, etanercept. The study is double‐blinded and placebo controlled using etanercept 50 mg subcutaneous injection twice weekly. For the first 3 months, one‐half of the patients will receive placebo and other half active drug. Neither patient nor investigator will know whether active drug or placebo is used. In the last 3 months, all patients will receive active drug. The purpose of the study is to evaluate etanercept effectiveness and adverse effects when used for HS. The study is still in progress, but preliminary results are encouraging.